Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Decreases By 14.3%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 38,210 shares, a drop of 14.3% from the January 29th total of 44,597 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 11,829 shares, the short-interest ratio is presently 3.2 days. Based on an average daily trading volume, of 11,829 shares, the short-interest ratio is presently 3.2 days. Approximately 2.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Alaunos Therapeutics has an average rating of “Sell”.

Alaunos Therapeutics Price Performance

NASDAQ:TCRT opened at $3.40 on Friday. Alaunos Therapeutics has a one year low of $1.31 and a one year high of $6.20. The company has a fifty day moving average price of $2.93 and a 200 day moving average price of $2.91. The stock has a market cap of $7.89 million, a P/E ratio of -1.47 and a beta of -1.29.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently bought a new stake in Alaunos Therapeutics stock. HRT Financial LP acquired a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned 0.54% of Alaunos Therapeutics as of its most recent filing with the Securities & Exchange Commission. 27.72% of the stock is owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.